The stock of Ascendis Pharma A/S Ads (NASDAQ:ASND) registered an increase of 3.56% in short interest. ASND’s total short interest was 538,700 shares in March as published by FINRA. Its up 3.56% from 520,200 shares, reported previously. With 28,200 shares average volume, it will take short sellers 19 days to cover their ASND’s short positions. The short interest to Ascendis Pharma A/S Ads’s float is 3.38%. The stock closed at $17.57 during the last session. It is down 2.23% since August 19, 2015 and is downtrending. It has underperformed by 0.13% the S&P500.
Ascendis Pharma A/S is a clinical stage biopharmaceutical company. The company has a market cap of $416.69 million. The Firm is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. It currently has negative earnings. The Firm is developing its lead product candidate, TransCon human growth hormone for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Ascendis Pharma A S - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.